Pharmaceutical composition comprising linagliptin and optionally a SGLT2 inhibitor, and uses thereof

Details for Australian Patent Application No. 2010212866 (hide)

Owner Boehringer Ingelheim International GmbH

Inventors Eisenreich, Wolfram

Agent Spruson & Ferguson

Pub. Number AU-A-2010212866

PCT Pub. Number WO2010/092124

Priority 61/152,306 13.02.09 US

Filing date 11 February 2010

Wipo publication date 19 August 2010

International Classifications

A61K 31/00 (2006.01)

A61K 31/522 (2006.01)

A61K 31/70 (2006.01) - Carbohydrates

A61K 31/7004 (2006.01) - Monosaccharides having only carbon, hydrogen and oxygen atoms

A61K 31/7008 (2006.01) - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61P 3/08 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

Event Publications

21 July 2011 PCT application entered the National Phase

  PCT publication WO2010/092124 Priority application(s): WO2010/092124

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010212867-Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof

2010212865-SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabete mellitus, impaired glucose tolerance or hyperglycemia